1132P Utility of circulating tumor DNA (ctDNA) dynamics for evaluating early treatment response in patients with recurrent/metastatic endometrial (rEC) and recurrent/platinum-resistant ovarian cancer (rPROC). - Cosgrove, C.; Backes, F.; Scalise, C.B.; Dwivedi, B.; Chambers, L.; Nagel, C.; Wei, L.; Hays, J.; Salmasi, F.; Dutta, P.; Kalashnikova, E.; Hook, N.; et al. (Annals of Oncology, 2025)